Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Dana Farber Partners Cancer Care, Inc.

Neither a doctor nor a teaching hospital

Research payments

$4,825,091

162 payments

Through program year 2025, Dana Farber Partners Cancer Care, Inc. is reported as receiving $4,825,091 in research payments, across 162 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $760,293 30
2024 Research $1,835,180 34
2023 Research $408,784 17
2022 Research $385,131 8
2021 Research $1,095,580 40
2020 Research $29,310 7
2019 Research $310,813 26

Breakdown

Who paid Research payments · program years 2019–2025
  1. Gilead Sciences, Inc. $3,993,504 100 payments
  2. Kite Pharma, Inc. $831,587 62 payments
Studies the money was for Research payments · program years 2019–2025
  1. SATEEN: A single-arm phase II trial of SAcituzumab govitecan and Trastuzumab after progrEssion on Enhertu $429,522 1 payment
  2. SATEEN: A single-arm phase II trial of SAcituzumab govitecan and Trastuzumab after progrEssion on Enhertu $408,610 1 payment
  3. SATEEN: A single-arm phase II trial of SAcituzumab govitecan and Trastuzumab after progrEssion on Enhertu $275,691 1 payment
  4. SATEEN: A single-arm phase II trial of SAcituzumab govitecan and Trastuzumab after progrEssion on Enhertu $275,691 1 payment
  5. Phase III Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed At Least Two Prior Chemotherapy Regimens $250,000 1 payment
  6. IMMU132-2019-021 / 19-578: A randomized phase 2 study of response-guided neoadjuvant SG followed by dose dense doxorubicin and cyclophosphamide (ddAC) or paclitaxel vs standard chemotherapy in patients with localized TNBC (NeoSTAR). $162,337 1 payment
  7. IMMU132-2019-021 / 19-578: A randomized phase 2 study of response-guided neoadjuvant SG followed by dose dense doxorubicin and cyclophosphamide (ddAC) or paclitaxel vs standard chemotherapy in patients with localized TNBC (NeoSTAR). $162,337 1 payment
  8. IMMU132-2019-028: SACI-IO TNBC Randomized phase II study of sacituzumab govitecan with or without pembrolizumab in PD-L1-negative metastatic triple negative breast cancer (TNBC) $149,321 1 payment
  9. Sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma progressing on platinum-based chemotherapy and PD1/L1 inhibitors: the Double Antibody Drug conjugate (DAD) $121,060 1 payment
  10. Sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma progressing on platinum-based chemotherapy and PD1/L1 inhibitors: the Double Antibody Drug conjugate (DAD) $121,060 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record